Oleg Novikov
Doctor of Pharmaceutical Sciences
Professor of the Department of Technology of Drug Production and Organization of Pharmaceutical Business of the Faculty of Advanced Training of Medical Workers of RUDN University,

Use the experience of previous generations.


Graduated from Kursk State Medical Institute (KSMI), Faculty of Pharmacy.

1988 - 1991

Postgraduate study at Kursk State Medical Institute, specialty “Pharmacist-researcher”.

1991 - 1994

Assistant of the Department of Analytical and Toxicological Chemistry of KSMU.


Candidate thesis on “Chemical-Toxicological study of furagin” was defended in the Perm Pharmaceutical Academy. The degree of Candidate of Pharmaceutical Sciences was awarded.

1994 - 2004

Researcher, senior lecturer, associate professor, professor of KSMU.

1996 - 2004

Head of the test center for food and pharmaceutical production in KSMU accredited in the system of the Ministry of Health and Gosstandart of Russia.


Doctoral thesis on “Formation of new approaches to the analysis and further use of drugs group 5-nitrofuran” was defended in Ryazan medical University.

2004 - 2005

Full-time employee of Belgorod State University (BelSU), head of analytical service of the enterprise “BelSU Pharmacy with production”.

2004 - 2016

Member of two dissertation councils (Kursk State Medical University) and Deputy Chairman of the dissertation Council (NRU “BelSU”).

2005 - 2006

Professor of the Department of Pharmacy and Deputy Dean of the Faculty of Medicine for research BelSU.

2006 - 2018

Head of the Department of Pharmaceutical Chemistry and Pharmacognosy Medical Institute of BelSU.

2016 - 2017

Expert of RAS.

2017 - present

Member of the joint dissertation Council D 999.197.03 in “Moscow Technological University”, NRU “BelSU”, All-Russian Scientific Research Institute of Medical and Aromatic Plants.

2016 - 2018

Member of the editorial Board of the journal “Scientific reports of BelSU. Series “Medicine, Pharmacy”.

2017 - 2018

Member of the editorial Board of the journal “Scientific result. Series “Medicine, Pharmacy”.

2018 - present

Director of drug quality control center SREC RUDN University.


Conducts courses for students of further education programs RUDN University:

  • “Pharmaceutical Chemistry and Pharmacognosy”,
  • “Pharmacology”.

The author of the following course-books and study guides:

“Drug quality control” Novikov O. O., Pisarev D. I. (Publishing house. Phoenix, 2018, 494 p. ISBN: 5222278492)

The study guide consists of two parts, including general methods of analysis and analysis of the drug quality of inorganic and organic nature. The first part describes the general methods of analysis, the possibility of using the melting and solidification temperature, the nature and structure of impurities and their impact on the qualitative and quantitative composition of the drug and the possibility of changing its pharmacological activity, methods for setting the limits of permissible impurities, pharmacopoeia tests for the most common impurities. In this part of the section the most important physical-chemical and chemical methods of analysis are described in detail. The second part presents the material on the analysis of drugs, groups and individual drugs, the study of which is necessary for the formation of professional horizons. This part consists of several sections, distributed according to the principles of the chemical structure of the studied compounds: preparations of inorganic structure, preparations of aliphatic, alicyclic, aromatic and heterocyclic structure.



  • The scientific direction “Pharmaceutical remake” - a complex of traditional and innovative technological, analytical and pharmacological operations (models), leading to the revival of previously known and now unused formulations and forms was created.
  • Drugs of group 5-nitrofuran from the position of pharmaceutical analysis were comprehensively studied and new directions for clinical study and use were formulated.
  • A number of chromatographic and spectral methods to quantify the group of 5-nitrofuran, major basic products and intermediates for their synthesis was presented;
  • Justified The possibility of applying in practice the antioxidant effects of drugs 5-nitrofuran series by the “feedback” mechanism using the tools of evidence-based pharmacology was substantiated.
  • Led the scientific direction “Development of methodological approaches to the analysis of natural and synthetic biologically active compounds in objects of different origin. Study of pharmacological aspects of the use of these biologically active compounds” in Belgorod National Research University (2010-2018).
  • The co-author of the idea of using the principle of internal standardization to adapt the matrix-activated laser desorption ionization (MALDI/TOF/MS) for the purpose of quantitative analysis of a wide range of molecules.
  • The co-author of the idea of using Mechanochemistry tools for processing pharmaceutical substances in order to give them different physical and technological characteristics.
  • The author/coauthor of more than 150 intellectual property objects in the field of pharmaceutical analysis, pharmaceutical technology and experimental pharmacology, the last of which is “Method of producing a composition for treatment of periodontal disease” (patent RU 2619338: as raw material for compositions use a mixture of juniper, cherry fruit and rhizomes of ginger); “Method of correction of microcirculatory disorders in the placenta at ADMA-like model of preeclampsia” (patent RU 2453000 can be used to study the mechanisms of correction of endothelial dysfunction in pregnant women); “Device for simulation of thermal burn” (patent RU 112478, utility model is designed for simulation of thermal burn in laboratory animals in order to develop methods of treatment of this pathology); “Medical and cosmetic herbal remedies for local use” (the Ukrainian patent for useful model No. 110799, the invention relates to a composition and technology of medical cosmetic herbal composition); “Aerosol packing with mixer” (patent RU 151287, the utility model is intended to expand the range of containers for pharmaceutical and other products); “The derived 3-(2,2,2-trimethylhydrazinium) propionate - 5- hydroxycinicotinate 3-(2,2,2-trimethylhydrazinium) propionate potassium, with endothelium-protective activity” (patent RU 2467744, the invention relates to the field of pharmaceutics and medicine, specifically to new chemical compound - a derivative of 3 - (2,2,2-Trimethylhydrazinium) propionate, namely 5- hydroxycinicotinate 3-(2,2,2-Trimethylhydrazinium) potassium propionate, which has increased endothelium-protective activity, which can be used in medicine in complex treatment for the correction of endothelial dysfunction in cardiovascular diseases).

Scientific interests

  • Pharmaceutical chemistry, analytical chemistry,
  • Toxicological chemistry,
  • Biopharmaceutical analysis,
  • Pharmaceutical technology,
  • Experimental pharmacology (natural biologically active compounds).
The aim of the article was to study and model solvent effects on phytocompounds' extraction from Glycyrrhizae radix for substantiation of rational choice of the extractant in the technology of drugs obtained from this type of plant raw material. The process of extraction was carried out by simple maceration for 24 h at temperature 25°C ± 1°C and extractant/plant raw material ratio 5:1 (v/w). The content of hydro-ethanolic extracts based on ethanol solutions with concentration of 22, 41, 50, 71, 82, and 96% ± 1% v/v and some other solvents was studied by reversed phase high-performance liquid chromatography. The optimal range of solvent concentration for simultaneous extraction of chalcones and glycyrrhizic acid derivatives from Glycyrrhizae radix was determined. It was found that dielectric constant of the solvent plays a key role in the distribution process of phytocompounds between the phases; there is a certain range of dielectric constant values of the solvent-water solution, within which maximum phytocompound concentration in the extract can be observed; the dependency between phytocompound concentration in the extract and dielectric constant of the solvent-water solution can be described by equation lnC = a + b/ϵ+d/ϵ.
This article presents the results of the development of technology for obtaining a thick extract of milk thistle fruits using ultrasonic treatment of plant material and extractant in the soaking stage. Materials and Methods: For the research, crushed fruits of milk thistle from “Biokor” Ltd, Penza, Russia, series 011216 were used, and the shelf life is 2 years. The particle size of the plant raw material is 0.5–1.0 mm. An aqueous solution of ethanol of 70% by volume was used as an extractant. Ultrasonic influence on the plant material and extractant were carried out under the following conditions: “Bandelin SONOPULS HD 3200” installation, ultrasonic frequency of 20 kHz, sound system of extracting system 5, 10, and 15 min, emitter power 280 W, and temperature 25°С. Results and its Discussion: It was found that with the ultrasonic treatment of raw materials and extractant in the soaking stage, the output of the phalavolignan complex almost doubles. To achieve the maximum concentration of flavonolignans in the extract, 5 min of ultrasound exposure to a mixture of raw material and extractant. Conclusions: The application of ultrasound at the stage of soaking plant material in the technology of obtaining a thick extract from the fruits of milk thistle is justified. It was shown that under the proposed conditions for extraction of flavonolignans from milk thistle, ultrasound promoted an increase in the yield of flavonolignans from plant raw materials and did not adversely affect these biologically active substances in the extract.
Two series of fibers containing the active ingredients acyclovir, ciprofloxacin and cyanocobalamin, and combinations of these drugs, were prepared by electrospinning. One set used the hydrophilic poly(vinylpyrrolidone) (PVP) as the filament-forming polymer, while the other used the slow-dissolving poly(ε-caprolactone) (PCL). The fibers were found to have cylindrical morphologies, although there was evidence for solvent occlusion with the PVP systems and for some drug particles in the PCL materials. The active ingredients were generally present in the amorphous physical form in the case of PVP, but evidence of crystallinity was observed with PCL. The existence of intermolecular interactions between the drugs and polymers was proven using simple molecular modeling calculations. Drug release from the various fibers was tested in a validated in vitro outflow model of the eye, and the fiber formulations found to be capable of extending drug release. We thus conclude that electrospun matrices such as those prepared in this work have potential for use as intravitreal implants.
The paper describes a retrospective analysis of the use of common betony in traditional and modern medicine. The Stachys plants have not been used in modern domestic medicine yet. Therefore, based on the historical experience of the use of common betony in traditional medicine, we have emphasized its value as a plant with high therapeutic potential. In this study, we used the socalled "Pharmaceutical remake", intended to revive interest in the now-forgotten objects of flora, which were previously widely used in medicine. The polyphenol structure of betony grass was studies with the use of the reverse-phase and graduate elution high-performance liquid chromatography. The presence of glycosides of diosmin, acacetin, luteolin and apigenin was established. The grass also contains hydroxycinnamic acids such as chlorogenic and rosemary acids, with the latter dominating in the polyphenol complex. The composition of plant terpenes in a hexane extraction has been studied by gas-liquid chromatography with mass spectrometric detection. It was determined that the terpenoid composition of betony is mainly represented by sesquiterpens: aromadendrene and germacrene, and monoterpenes: 3-carene and dihydrocarveol.